Fell to 43%, down approximately 410 basis points from the prior year; decrease stems mainly from cost deleverage, royalty ...

Well, good morning, everyone, and welcome to Cullinan Therapeutics Immunology Day. Today is an important milestone for Cullinan and also the way autoimmune diseases may be treated in the future. As ...